Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King’s Cardiac Imaging Drug Binodenoson Gets Committee Review

This article was originally published in The Pink Sheet Daily

Executive Summary

CorVue would compete with Astellas’ Lexiscan in a market that has seen many product development failures recently.

You may also be interested in...



Micardis Cardiovascular Prophylactic Indication Faces Advisory Panel Scrutiny

Telmisartan is noninferior to ramipril (the now generic Altace), Boehringer Ingelheim says.

Micardis Cardiovascular Prophylactic Indication Faces Advisory Panel Scrutiny

Telmisartan is noninferior to ramipril (the now generic Altace), Boehringer Ingelheim says.

Micardis Expanded Prophylactic Indication Faces Safety Hurdle

FDA’s cardio-renal advisory committee meets July 29 to assess comparative data to ramipril (the now generic Altace).

Related Content

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel